Pricing Log in Create free account

AgomAb Therapeutics NV (AGMB) vs Opus Genetics, Inc. (IRD)

AgomAb Therapeutics NV and Opus Genetics, Inc. are both Biotechnology companies. AgomAb Therapeutics NV and Opus Genetics, Inc. are of similar size ($343.3M and $333.2M). Across the 6 metrics below, AgomAb Therapeutics NV leads on 3 and Opus Genetics, Inc. on 3.

Valuation

Metric AGMB IRD Biotechnology median
P/E — n/m 10.60
P/S — 40.40 9.40
P/B n/m n/m 2.13
Price to free cash flow n/m n/m 25.18
EV/EBITDA n/m n/m 0.66
EV/Sales n/m 34.95 9.02
Earnings yield — (30.94%) (32.88%)
Free cash flow yield 0.00% (10.61%) (23.13%)

Profitability

Metric AGMB IRD Biotechnology median
Gross margin — 100.00% 68.51%
Operating margin — (513.47%) 0.00%
Net margin — (1,091.82%) 0.00%
Free cash flow margin 0.00% (412.61%) 0.00%
Return on equity — (4,796.52%) (51.96%)
Return on assets — (163.50%) (46.06%)
Return on invested capital 0.00% 0.00% 0.00%

Growth

Metric AGMB IRD Biotechnology median
Revenue growth (TTM) — (36.09%) 6.76%
EPS growth (last fiscal year) (39.80%) 62.79% 29.88%
Revenue growth, 5-year CAGR — — 9.75%
Net income growth, 5-year CAGR — 0.00% 0.00%

Health

Metric AGMB IRD Biotechnology median
Debt to equity 0.00 (2.69) 0.00
Current ratio 12.88 12.19 4.97
Net debt to EBITDA 1.96 1.17 1.01

Dividend

Metric AGMB IRD Biotechnology median
Dividend yield — — 0.41%
Payout ratio — — —

Size

Metric AGMB IRD Biotechnology median
Market cap 343.27m 333.20m 161.82m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack